One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
The intervention probably leads to higher adverse events rate‐Diarrhea (moderate certainty).
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with anti TNF‐α (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether elemental changes withdrawal due to adverse events compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).